Cereno Scientific AB Stock OTC Markets
Stocks
CRNOF
SE0008241558
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
OTC Markets
11:03:07 2026-05-07 EDT
|
5-day change | 1st Jan Change | ||
| 0.6315 USD | +0.24% |
|
-.--% | +0.24% |
| 09-25 | Cereno Scientific Reports Positive Topline Results from CS014 Phase I Pk-Bridging Study | CI |
| 09-25 | RX Securities reiterates buy on Cereno Scientific following positive Phase 1 data for CS014 | FW |
| Market Cap | 1.15B 115M 103M 96.06M 87.17M 164M 11.16B 166M 450M 5.69B 433M 424M 18.34B | P/E 2026 * |
-8.07x | P/E 2027 * | -6.4x |
|---|---|---|---|---|---|
| Enterprise Value | 1.36B 136M 122M 114M 103M 194M 13.2B 196M 532M 6.73B 512M 501M 21.68B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
90.9% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | +0.24% | ||
| 6 months | +0.24% | ||
| Current year | +0.24% |
| Current year | 0.63 |  | 0.63 |
| 1 year | 0.63 | | 0.63 |
| 3 years | 0.63 | | 0.99 |
| 5 years | 0.63 | | 0.99 |
| 10 years | 0.63 | | 0.99 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 67 | 2015-08-31 | |
Eva Jagenheim
DFI | Director of Finance/CFO | 60 | 2023-08-27 |
| Chief Tech/Sci/R&D Officer | 40 | 2023-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 67 | - | |
| Director/Board Member | 73 | 2023-12-31 | |
Anders Svensson
BRD | Director/Board Member | 75 | 2018-10-22 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.24% | -.--% | - | - | 116M | |
| -3.19% | -3.19% | +44.60% | +87.98% | 74.68B | |
| -15.86% | -16.67% | +3.92% | +50.90% | 58.7B | |
| -2.39% | -2.05% | +4.29% | +31.33% | 48.36B | |
| -6.35% | -8.35% | +303.95% | +651.28% | 43.05B | |
| +0.30% | -3.71% | +28.89% | +30.33% | 42.48B | |
| -3.82% | -4.32% | +2.49% | +101.36% | 41.39B | |
| -2.13% | +1.07% | +7.51% | +50.31% | 31.29B | |
| -3.35% | -6.35% | -13.20% | -17.22% | 23.93B | |
| -1.24% | -11.97% | -38.10% | +311.13% | 22.22B | |
| Average | -3.78% | -2.63% | +38.26% | +144.16% | 42.9B | |
| Weighted average by Cap. | -4.86% | -1.88% | +44.70% | +136.42% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -139M -13.96M -12.45M -11.63M -10.55M -19.87M -1.35B -20.07M -54.48M -689M -52.4M -51.28M -2.22B | -176M -17.69M -15.77M -14.73M -13.37M -25.17M -1.71B -25.42M -69.01M -873M -66.38M -64.96M -2.81B |
| Net Debt | 209M 21.01M 18.74M 17.5M 15.88M 29.9M 2.03B 30.19M 81.98M 1.04B 78.85M 77.16M 3.34B | 545M 54.63M 48.73M 45.5M 41.29M 77.75M 5.29B 78.52M 213M 2.7B 205M 201M 8.69B |
Employees
10
Calendar
| Date | Price | Change | Volume |
|---|
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.550SEK
Average target price
20.00SEK
Spread / Average Target
+463.38%
Annual profits - Rate of surprise
- Stock Market
- Stocks
- CRNO B Stock
- CRNOF Stock
Select your edition
All financial news and data tailored to specific country editions
